Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re ...

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...

In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor ...

The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Eli Lilly’s Omvoh is rapidly ...